Global Health Partnership Announces New AIDS Drugs Price Reduction Deal

A new deal that reduces the prices of key HIV/AIDS medicines is expected to boost access to treatment and care among HIV patients in developing countries.

A global health partnership composed of UNITAID, the Clinton Health Access Initiative and the U.K. Department for International Development brokered the deal, which cuts the prices of two generic HIV/AIDS drugs by up to 60 percent from the medicines’ 2008 prices. The agreement is part of a broader effort to reduce the prices of new-generation medicines that would otherwise be too expensive for poor countries to afford, Reuters says.

Through the deal, a first-line regimen using the drug tenofovir would now cost less than $159 per patient per year, which is approximately 60 percent lower than what it cost in 2008. A second-line treatment regimen recommended by the World Health Organization will also cost less at $410 per patient year, down from $800 to $1,200 in 2008.

These treatment regimens are increasingly being adopted by developing countries, and the deal, along with similar ones secured since 2008, would help generate up to $600 million in savings in the next three years, the partnership said, according to Reuters.

Read more development aid news.

About the author

  • Ivy Mungcal

    As former senior staff writer, Ivy Mungcal contributed to several Devex publications. Her focus is on breaking news, and in particular on global aid reform and trends in the United States, Europe, the Caribbean, and the Americas. Before joining Devex in 2009, Ivy produced specialized content for U.S. and U.K.-based business websites.